Will Misonix retain all of its present rights for the Sonablate 500 and the distribution rights for the treatment of kidney, liver and breast tissue? Is the introduction and sales of the SonaStar Ultrasonic Surgical Aspiration System into Ecuador successful?
IIP > read on here > http://www.businesswire.com…
…Misonix, Inc. (NASDAQ: MSON), a developer of minimally invasive ultrasonic medical device technology for the ablation of cancer and other chronic health conditions, today reported financial results for its fiscal year 2008 third quarter ended March 31, 2008…
Revenues for the third quarter were $11.8 million, up 11.5%, compared to $10.6 million for the three months ended March 31, 2007. The increase in revenues was due to a $487,000 increase in medical device products sales to $6.5 million and a $732,000 increase in sales of laboratory and scientific products to $5.3 million.
The increase in revenues of medical and diagnostic device products of $487,000 was primarily due to increased sales of the Company’s ultrasonic assisted liposuction and surgical aspirator products. Sales of the SB500® product in the third quarter, a High Intensity Focused Ultrasound (“HIFU”) treatment for prostate cancer, were lower by approximately $485,000 due to the ongoing implementation of a fee-per-use model as an alternative to capital equipment sales. This strategy is intended to deliver a longer life span of revenues and is expected to accelerate market penetration of HIFU…
The Company reported a backlog of unfilled orders as of March 31, 2008 of $11.4 million compared to $10.7 million as of December 31, 2007. Medical device products backlog was $6.4 million and laboratory and scientific products backlog was $5.0 million…
Misonix, Inc… designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc., which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Post a Comment